Evaluation of the safety and benefit of phase I oncology trials for patients with primary CNS tumors Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Central Nervous System Neoplasms
  • Clinical Trials, Phase I as Topic
  • Research Design

abstract

  • Patients with HGG who meet standard eligibility criteria may be good candidates for solid tumor phase I studies with single-agent molecular or cytotoxic drugs with favorable preclinical rationale and pharmacokinetic properties in this population.

publication date

  • October 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4857195

Digital Object Identifier (DOI)

  • 10.1200/JCO.2015.61.1525

PubMed ID

  • 26282642

Additional Document Info

start page

  • 3186

end page

  • 92

volume

  • 33

number

  • 28